Abstracts tagged "Comorbidity"

Abstract Number: 0223 • ACR Convergence 2024
A Comparative Study of Difficult-to-Treat vs Non-Difficult-to-Treat Psoriatic Arthritis for Disease Burden and Comorbidities: An Ultrasound Study
Ricardo Sabido-Sauri¹, Seyyid Bilal Acikgoz², Ozun Bayindir Tsechelidis³, Ummugulsum Gazel¹, Sylvia Sangwa⁴, Elliot Hepworth¹ and Sibel Aydin⁵, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: In the era of several advanced therapies and an increased number of patients with psoriatic arthritis (PsA) who have been failed by multiple treatment…
Abstract Number: 1245 • ACR Convergence 2024
Inpatient Discontinuation of Allopurinol – A Quality Improvement (QI) Initiative
Stephanie Tancer¹, Basmah Al Dulaijan² and Puja Khanna³, ¹University of Michigan Department of Internal Medicine, Division of Rheumatology, Ann Arbor, MI, ²Michigan Medicine, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Gout is a chronic inflammatory arthritis induced by hyperuricemia and manifested by recurrent acute flares of debilitating joint pain when left untreated. Allopurinol is…
Abstract Number: 2321 • ACR Convergence 2024
Prevalence and Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease
Nahia Plaza-Aulestia¹, Oihane Ibarguengoitia-Barrena², Blanca Sampedro-Andrada³, Cristina San Juan-Lopez³, Victoria Morillo-Montañes⁴, Irati Urionaguena⁵, Itziar Calvo⁶, David Montero Seisdedos⁷, Lucia Vega-Alvarez², Jose Francisco Garcia Llorente² and Nuria Vegas Revenga⁸, ¹Rheumatology Division, Galdakao-Usansolo University Hospital, Galdakao, Spain, ²Rheumatology Division, Galdakao-Usansolo University Hospital, Bilbao, Spain, ³Digestive Division, Galdakao-Usansolo University Hospital, Galdakao, Spain, ⁴Dermatology Division, Galdakao-Usansolo University Hospital, Galdakao, ⁵Rheumatology Division, Galdakao-Usansolo University Hospital, GERNIKA-LUMO, Spain, ⁶Hospital Universitario de Basurto, Bilbao, Spain, ⁷Galdakao-Usansolo University Hospital, Bilbao, Spain, ⁸Hospital Galdakao- Usansolo, Galdakao, Spain
Background/Purpose: Patients with psoriatic disease (PsD) [psoriasis (PsO) and psoriatic arthritis (PsA)] are at greater risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD) compared…
Abstract Number: 0292 • ACR Convergence 2024
Liver Disease Complicating Familial Mediterranean Fever: A Study on 57 Patients from the French Adult JIR Cohort
Marion Delplanque¹, xavier amiot², Dominique Wendum³, françois Rodrigues², Rim bourguiba¹, Benoit Terris⁴, Christophe Duvoux², Pierre Bedossa⁵, Didier lebrec⁵, Philippe Sogni², Lucia parlati², Frederic Charlotte², Vlad Ratziu², stephane mouly⁶, jeremy augustin², julien Calderaro², giovana scoazec², JM Vignaud⁷, JA Seyrig⁸, Gilles Grateau¹, Lea Savey⁹ and Sophie Georgin-lavialle¹⁰, ¹Internal Medicine Department, Tenon Hospital, AP-HP, Paris, France, Paris, France, ²APHP, Paris, ³APHP, Paris, France, ⁴Department of pathology, Hôpital Cochin, GHU Paris Centre, AP-HP, Université Paris Cité,, Paris, France, ⁵APHP, clichy, ⁶Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, ⁷CHRU nancy, Nancy, ⁸CH centre bretagne, pontivy, ⁹Internal Medicine Department, Tenon Hospital, AP-HP, Paris, France, france, France, ¹⁰Sorbonne Université, Department of internal medicine, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
Background/Purpose: Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease, associated with MEFV gene mutations. FMF patients can experience liver involvement, potentially leading…
Abstract Number: 1248 • ACR Convergence 2024
Most Prevalent Self-Reported Comorbidities Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis
Shilpa Venkatachalam¹, Jeffrey Curtis², Anne Sydor³, Erik Stone⁴, Angela Degrassi³, Esteban Rivera⁵, Laura Stradford⁶ and Kelly Gavigan³, ¹Global Healthy Living Foundation, New York, NY, ²University of Alabama at Birmingham, Hoover, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Upper Nyack, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶Global Healthy Living Foundation, Nyack, NY
Background/Purpose: Many people with inflammatory arthritis live with other serious chronic conditions that may affect their quality of life and ability to effectively manage their…
Abstract Number: 2337 • ACR Convergence 2024
Patient Characteristics and Outcomes of Emergency Visits in Psoriatic Arthritis: Results from the U.S. Nationwide Emergency Department Sample (NEDS)
Dominique Feterman Jimenez¹, Rachael Stovall¹, Jose Andres Porres Arnaez², Vishwesh Bharadiya³, Jean Liew⁴, Alison Bays¹, Thomason Jenna⁵, Londyn Robinson⁶, Rashmi Dhital⁷ and Namrata Singh⁸, ¹University of Washington, Seattle, WA, ²Universidad Francisco Marroquin, Guatemala, ³AIIMS, New Delhi, India, ⁴Boston University, Boston, MA, ⁵University of Washington, Division of Rheumatology, Seattle, WA, ⁶University of Washington, Durham, NC, ⁷UC San Diego, Brentwood, TN, ⁸University of Washington, Bellevue, WA
Background/Purpose: Compared with the general population, patients with psoriatic arthritis (PsA) have a higher risk of comorbidities and all-cause mortality. They are also at increased…
Abstract Number: 0310 • ACR Convergence 2024
I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study
Amine Mouamnia, Armentieres Hospital Center, Armentieres, France
Background/Purpose: Inflammatory and auto-immune disease are associated to comordities. Indeed, patients suffering from arthritis rheumatoid disease (ARD) such as rheumatoid arthritis (RA), polymyalgia rheumatica (PMR)…
Abstract Number: 1332 • ACR Convergence 2024
Financial Distress and Its Determinants in Adults with Rheumatoid Arthritis
Amber Brown Keebler¹, Yunju Im², Sofia Pedro³, Ted Mikuls¹, Edward Peters¹ and Kaleb Michaud¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Often not evaluated in clinical visits, financial distress associated with medical costs, also known as financial toxicity, has emerged as an important factor affecting…
Abstract Number: 2388 • ACR Convergence 2024
Racial/Ethnic Variation in Multimorbidity Risk and Accrual and Comorbid Conditions Among Patients with Systemic Lupus Erythematosus
Katrina Williamson¹, Herbert Heien², Maria Stevens², Cynthia Crowson², Rozalina McCoy² and Ali Duarte-Garcia², ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have been shown to have increased burden of multimorbidity. Racial disparities in multimorbidity have also been shown repeatedly.…
Abstract Number: 0409 • ACR Convergence 2024
Differences in Clinical Presentation and Outcomes Between Down Syndrome-Associated Arthritis and Juvenile Idiopathic Arthritis
Irene Chern¹, Jade Singleton², Xing Wang³ and Jordan Jones⁴, ¹St. Christopher's Hospital for Children, Philadelphia, PA, ²Seattle Children's Hospital, Seattle, ³Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, ⁴Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Down syndrome (DS), a disorder caused by triplication of chromosome 21, affects around 1 in 1000 births making it one of the most common…
Abstract Number: 1336 • ACR Convergence 2024
Risk of Malignancy Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
Ryoko Sakai¹, Eiichi Tanaka², Eisuke Inoue³ and Masayoshi Harigai⁴, ¹Meiji Pharmaceutical University, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Showa University, Tokyo, Japan, ⁴Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Janus kinase inhibitors (JAKIs) have shown positive therapeutic impacts on treatments for rheumatoid arthritis (RA), whereas, there are concerns about the risk of malignancy…
Abstract Number: 2467 • ACR Convergence 2024
Elderly Systemic Sclerosis. Clinical Presentation and Outcome
Miriam Retuerto Guerrero¹, Clara Moriano², cristiana sieiro santos³, Ismael Gonzalez⁴, Ignacio Gonzalez Fernandez⁵, Carolina Díez Morrondo⁵, Carolina Alvarez Castro⁶, Paula Perez Garcia⁵, Jose Ordas Martínez⁵, Pedro Baenas Gonzalez⁵ and elvira Diez álvarez⁵, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁴Complejo Asistencial Universitario de Leon, León, Spain, ⁵Complejo Asistencial Universitario de Leon, Leon, ⁶Complejo Asistencial Universitario de Leon, Leon, Spain
Background/Purpose: Immunosenescence refers to the gradual deterioration of the immune system associated with aging, leading to an increased incidence of infections, cancer, and autoimmune diseases.…
Abstract Number: 0481 • ACR Convergence 2024
Differential Effect of Comorbidities on the Clinical Evolution of Early Arthritis by Sex
Marina Dueñas¹, Juan Carlos Sáez¹, María Paula Álvarez², Patricia Quiroga¹, Maryia Nikitsina³, Rosario García-Vicuña², Ana Ortiz⁴, Isidoro González-Álvaro³ and Irene Llorente-Cubas⁴, ¹Servicio de Reumatología Hospital La Princesa, Madrid, Madrid, Spain, ²Hospital Universitario de La Princesa, Madrid, Madrid, Spain, ³University Hospital La Princesa, Madrid, Madrid, Spain, ⁴Hospital Universitario de La Princesa, Madrid, Spain
Background/Purpose: The prevalence of comorbidities is increased in patients with rheumatoid arthritis (RA) compared to the general population1, but their impact in the earlier stages…
Abstract Number: 1340 • ACR Convergence 2024
Characteristics and Long-term Outcomes of Patients with Rheumatoid Arthritis and Concurrent Calcium Pyrophosphate Deposition Disease
Natalie Schanzer¹, Ted Mikuls², Bryant England², Katherine Wysham³, Jorge Rojas⁴, Sauer brian⁵, Beth Wallace⁶, Rachel Elam⁷, Andreas Reimold⁸, Gail Kerr⁹, John Richards¹⁰, Gary Kunkel¹¹, Iris Lee¹², Isaac Smith¹³, Paul Monach¹⁴, grant Cannon¹⁵ and Joshua Baker¹⁶, ¹Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Seattle VA, Mexico, Mexico, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁷Augusta University, Evans, GA, ⁸Dallas VA Medical Center, Dallas, TX, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹¹University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹²Washington University in St Louis, Saint Louis, MO, ¹³Duke University Hospital, Durham, NC, ¹⁴VA Boston Healthcare System, Boston, MA, ¹⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common crystalline arthritis that can both present alongside rheumatoid arthritis (RA) and, given its similar pattern of…
Abstract Number: 2612 • ACR Convergence 2024
Two-Week Methotrexate Discontinuation in Autoimmune Rheumatic Diseases Patients Vaccinated with Recombinant Herpes Zoster Vaccine: An Interim Analysis of a Prospective Randomized Phase 4 Study
Ana Cristina Medeiros-Ribeiro¹, Joao de Oliveira², Nadia Aikawa³, Sandra Pasoto², Leonard Kupa², Carla Goncalves Schahin Saad⁴, Luciana Parente², ANA PAULA ASSAD², Eduardo Borba², Emily Figueiredo Neves Yuki², Andrea Shimabuco⁴, Karina Bonfiglioli², Diogo Domiciano², Percival Sampaio-Barros⁴, Andre Franco², Julio Moraes⁵, Murillo Dorio², Claudia Goldenstein-Schainberg², Henrique Carriço Da Silva², Lucas Guimarães², Fernanda Chaer⁶, Caio Laguna Reis de Carvalho², Henrique Dalmolin², Clovis Silva⁷ and Eloisa Bonfa², ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Santos, Brazil, ⁷Rheumatology Division and Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Temporary methotrexate (MTX) discontinuation may enhance vaccine immune response, but there are no data for the recombinant zoster vaccine (RZV). This study assessed if…

1
2
3
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].